» Articles » PMID: 29268541

Molecular Targets in Aortic Aneurysm for Establishing Novel Management Paradigms

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2017 Dec 23
PMID 29268541
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Aortic aneurysm (AA) is a lethal disease and presents a large challenge for surgeons in the clinic. Although surgical management remains the major choice of AA, operative mortality remains high. With advances in understanding of the mechanisms of AAs, molecular targets, such as matrix metalloproteinases (MMPs), D-dimer, and inflammation markers, including C-reactive protein, interleukins and phagocytes, are important in the pathology of development of AA. These markers may become important for improving the diagnostic quality and provide more therapeutic choices for treatment of AA. Although these new markers require long-term trials before they can be translated into the clinic, they can still be helpful in determining new directions. The main aim of this review is to discuss the current findings of molecular targets in progression of AA and discuss the potential application of these new targets for managing this disease.

Citing Articles

Using Molecular Targets to Predict and Treat Aortic Aneurysms.

Zhou X, Liu G, Lai H, Wang C, Li J, Zhu K Rev Cardiovasc Med. 2024; 23(9):307.

PMID: 39077712 PMC: 11262374. DOI: 10.31083/j.rcm2309307.


Predictions and insights for the abdominal aortic aneurysm.

Kotsis T J Thorac Dis. 2019; 10(11):5982-5984.

PMID: 30622768 PMC: 6297402. DOI: 10.21037/jtd.2018.10.15.


PARP-1 (Poly[ADP-Ribose] Polymerase-1).

Alves-Lopes R, Touyz R Hypertension. 2018; 72(5):1087-1089.

PMID: 30354832 PMC: 6218001. DOI: 10.1161/HYPERTENSIONAHA.118.11830.

References
1.
Kotze C, Menezes L, Endozo R, Groves A, Ell P, Yusuf S . Increased metabolic activity in abdominal aortic aneurysm detected by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT). Eur J Vasc Endovasc Surg. 2009; 38(1):93-9. DOI: 10.1016/j.ejvs.2008.12.016. View

2.
Lindeman J, Abdul-Hussien H, van Bockel J, Wolterbeek R, Kleemann R . Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation. 2009; 119(16):2209-16. DOI: 10.1161/CIRCULATIONAHA.108.806505. View

3.
Wilson W, Anderton M, Choke E, Dawson J, Loftus I, Thompson M . Elevated plasma MMP1 and MMP9 are associated with abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg. 2008; 35(5):580-4. DOI: 10.1016/j.ejvs.2007.12.004. View

4.
Liapis C, Paraskevas K . The pivotal role of matrix metalloproteinases in the development of human abdominal aortic aneurysms. Vasc Med. 2004; 8(4):267-71. DOI: 10.1191/1358863x03vm504ra. View

5.
Baxter B, Pearce W, Waltke E, Littooy F, Hallett Jr J, Kent K . Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg. 2002; 36(1):1-12. DOI: 10.1067/mva.2002.125018. View